로베나콕시브
Robenacoxib
5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl acetic acid
다른 이름: Onsior · robenacoxibum · robénacoxib
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
동물 종별 용량
🌎 NA — North America🌍 EU — Europe
개
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Pain and inflammation associated with chronic osteoarthritis | 1 mg/kg with a range of 1-2 mg/kg | PO | once daily | Discontinue after 10 days if no clinical improvement seen | 🌎 NA |
| Pain and inflammation associated with orthopedic or soft tissue surgery | 2 mg/kg | SC | once | — | 🌎 NA |
| Perioperative analgesia (orthopaedic and soft tissue surgery) | 2 mg/kg | SC | q24h | Maximum of 2 doses | 🌍 EU |
| Acute and chronic musculoskeletal disorders | 1-2 mg/kg | PO | q24h | Discontinue after 10 days if no clinical improvement | 🌍 EU |
- Pain and inflammation associated with chronic osteoarthritis: Give at the same time every day. For long term treatment, can adjust to lowest effective dose.
- Pain and inflammation associated with orthopedic or soft tissue surgery: Administer approximately 30 minutes before the start of surgery.
- Perioperative analgesia (orthopaedic and soft tissue surgery): Administer approximately 30 minutes before the start of surgery.
- Acute and chronic musculoskeletal disorders: Do not administer with food. Monitoring is recommended for long-term treatment (>12 weeks).
고양이
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Acute pain and inflammation associated with musculoskeletal disorders | 1 mg/kg; with a range of 1-2.4 mg/kg | PO | once daily | up to 6 days | 🌎 NA |
| Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation) | 2 mg/kg | SC | once | — | 🌎 NA |
| Perioperative analgesia | 2 mg/kg | SC | q24h | Maximum of 2 doses | 🌍 EU |
| Acute and chronic musculoskeletal pain and inflammation | 1-2 mg/kg | PO | q24h | As directed by veterinarian | 🌍 EU |
- Acute pain and inflammation associated with musculoskeletal disorders: Equates to 1 tablet for cats weighing 2.5-<6 kg and 2 tablets for cats weighing 6 kg-<12 kg. Give either without food or with a small amount of food; tablets should not be divided or broken.
- Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation): Administer approximately 30 minutes before the start of surgery.
- Perioperative analgesia: Administer approximately 30 minutes before the start of surgery.
- Acute and chronic musculoskeletal pain and inflammation: May be mixed with a small amount of food. Monitoring is recommended for long-term treatment (>12 weeks).
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
로베나콕시브 (Robenacoxib) 는 개와 고양이용으로 특별히 승인된 고선택성 콕시브계 비스테로이드성 항염증제(NSAID)입니다.
주요 임상적 특징은 다음과 같습니다:
- 조직 선택성: 혈류에서는 빠르게 제거되지만, 활성 염증 부위(예: 염증이 생긴 관절)에서는 더 높은 농도로 더 오래 지속되는 독특한 약동학적 프로파일을 보입니다. 이러한 "조직 보존" 효과는 전신 부작용을 최소화하면서 효능을 극대화하는 데 도움이 됩니다.
- 높은 COX-2 특이성: COX-1에 비해 개에서는 약 140배, 고양이에서는 500배 더 COX-2에 선택적으로 작용하여, 수의학에서 사용 가능한 가장 COX-2 특이적인 NSAID 중 하나입니다.
- 적응증: 주로 개의 만성 골관절염 통증, 고양이의 급성 근골격계 통증, 그리고 두 종 모두에서 연부 조직 또는 정형외과 수술과 관련된 주술기 통증 관리에 사용됩니다.
작용 기전
Robenacoxib exerts its anti-inflammatory and analgesic effects by selectively inhibiting the Cyclooxygenase-2 (COX-2) enzyme.
Arachidonic Acid → COX-2 Enzyme → Prostaglandin E2 (PGE2) and other inflammatory mediators.
By specifically targeting the inducible COX-2 isoform, robenacoxib effectively blunts the production of prostaglandins responsible for pain, inflammation, and fever. Because it largely spares the constitutive COX-1 enzyme, it preserves the homeostatic prostaglandins that are crucial for maintaining gastrointestinal mucosal integrity, renal blood flow, and normal platelet function.
안전성·주의사항
금기사항
- Patients with active gastrointestinal ulcers
- Hypersensitivity to robenacoxib or its excipients
- Dogs with hepatic disease
- Dehydrated, hypovolaemic, or hypotensive patients
- Patients with pre-existing gastrointestinal disease or ulceration
- Patients with blood clotting disorders
- Pregnant or lactating animals
- Dogs < 12 weeks of age or < 2.5 kg body weight
- Cats < 16 weeks of age or < 2.5 kg body weight
- Perioperative use in animals with renal disease (not advisable)
부작용
- Decreased appetite
- Blood in feces (melena/hematochezia)
- Mild gastrointestinal signs (vomiting, soft feces, diarrhea)
- Gastrointestinal ulceration or bleeding (rare but severe)
- Renal toxicity (especially if hypotensive or dehydrated)
- Hepatic accumulation (in patients with pre-existing liver disease)
주의
Strict Veterinary Monitoring Required: Use with extreme caution in patients with impaired cardiac or renal function, dehydration, hypovolemia, hypotension, or in cats with hepatic dysfunction.
- Washout Period: Do not use concurrently with corticosteroids or other NSAIDs. A treatment-free period of at least 24 hours (accounting for the half-life of the previous drug) should be observed before starting robenacoxib.
- Renal Perfusion: Use cautiously with drugs that affect renal blood flow (e.g., diuretics, ACE inhibitors) due to the risk of renal toxicity.
- Reproduction: Safety has not been established in pregnant or lactating animals; use is not recommended.
약물 상호작용
Some NSAIDs can reduce effects on blood pressure
May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
NSAIDs may increase serum levels
Administration has increased plasma levels of celecoxib in humans and potentially could also affect robenacoxib levels in dogs
NSAIDs may reduce the saluretic and diuretic effects
As robenacoxib is highly bound to plasma proteins (>99%), it may displace other highly bound drugs or be displaced by them, potentially leading to increased serum levels and toxicity
Serious toxicity has occurred when NSAIDs have been used concomitantly; use together with extreme caution
May enhance the risk of nephrotoxicity development
Increased risk of severe gastrointestinal ulceration and renal toxicity. Require a 3-5 day wash-out period.
Increased risk of severe gastrointestinal ulceration and bleeding.
Increased risk of nephrotoxicity.
모니터링
- Baseline and periodic physical examinations to assess clinical efficacy and adverse effects
- Baseline and periodic CBC, serum biochemistry (liver and renal function), electrolytes, and urinalysis
- For long-term therapy in dogs: Monitor liver enzymes at the start of therapy, and after 2, 4, and 8 weeks; then every 3-6 months
- Discontinue therapy if liver enzymes increase markedly or if accompanied by clinical signs (anorexia, apathy, vomiting)
- Clinical response (reduction in pain and inflammation)
- Gastrointestinal signs (monitor for vomiting, diarrhea, or melena)
- Renal parameters (BUN, Creatinine, USG) and hepatic enzymes, especially prior to anesthesia or during long-term therapy (>12 weeks)
약동학
반감기
흡수
Peak blood concentrations occur approximately 30 minutes after dosing in both dogs and cats. In dogs, food decreases peak levels somewhat. In cats, a small amount of food does not impact absorption.
분포
Highly bound to plasma proteins (>99%). Robenacoxib persists longer and at higher concentrations at sites of inflammation (e.g., inflamed joints) than in the central blood compartment.
대사
Extensively metabolized by the liver in both dogs and cats. It does not appear to induce hepatic enzymes in dogs.
배설
In dogs, excretion is primarily biliary (~65%) with the remainder excreted renally. In cats, elimination is 70% biliary and 30% renal.
과다투여
Acute overdoses may potentially cause gastrointestinal, kidney, or liver toxicity.
Interestingly, chronic toxicity studies in healthy young dogs (up to 10 mg/kg/day for 6 months) and cats (up to 10 mg/kg SC for 3 days) did not produce signs of toxicity.
Treatment: If an acute overdose occurs, symptomatic and supportive therapy is recommended. This may include the administration of gastrointestinal protective agents (e.g., sucralfate, omeprazole), IV fluid therapy for forced diuresis and renal support, and contacting an animal poison control center for guided management.
제품
제형
- Flavored oral tablets (canine and feline)
- Solution for injection
- 5 mg flavoured tablets (dogs)
- 10 mg flavoured tablets (dogs)
- 20 mg flavoured tablets (dogs)
- 40 mg flavoured tablets (dogs)
- 6 mg flavoured tablets (cats)
- 20 mg/ml injectable solution
동물용의약품
- Robenacoxib Flavored Oral Tablets (dogs): 5 mg, 10 mg, 20 mg, 40 mg
- Robenacoxib Flavored Tablets (cats): 6 mg
- Robenacoxib Solution for Injection: 20 mg/mL in 20 mL multi-dose vials
- Onsior 5 mg flavoured tablets for dogs
- Onsior 10 mg flavoured tablets for dogs
- Onsior 20 mg flavoured tablets for dogs
- Onsior 40 mg flavoured tablets for dogs
- Onsior 6 mg flavoured tablets for cats
- Onsior 20 mg/ml solution for injection
규제 현황
POM-V classification
POM-V classification
규제 데이터 없음: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Store canine flavored tablets at 25°C (77°F) or less. Store feline flavored tablets at no more than 30°C (86°F). The injection should be stored in the refrigerator (2°-8°C) in its original outer carton.
보호자 정보
온시어® (로베나콕시브) 는 반려동물의 통증과 염증을 완화하는 데 사용되는 약물입니다. 안전하고 효과적인 사용을 위해 다음 지침을 따라주세요:
- 반려견의 경우: 공복에 투여하십시오. 식사 최소 30분 전이나 후에 약을 먹이세요.
- 반려묘의 경우: 음식 없이 주거나 소량의 음식과 함께 줄 수 있습니다. 알약을 쪼개거나 부수지 마십시오.
- 취급 주의사항: 약을 만진 후에는 손을 씻으십시오. 출산이 임박한 임산부는 이 약을 취급할 때 장갑을 착용해야 합니다.
- 주의해야 할 증상: 반려동물에게 다음과 같은 이상 징후가 나타나면 즉시 약 투여를 중단하고 수의사에게 연락하십시오:
- 심하거나 피가 섞인 구토 또는 설사
- 식욕 부진 또는 극심한 무기력증
- 눈의 흰자위나 잇몸이 노랗게 변함 (황달)
- 쓰러짐 또는 쇠약
- 수의사와 상담하지 않고 이 약을 복용하는 동안 다른 진통제(아스피린, 이부프로펜 또는 다른 동물용 NSAID 등)나 스테로이드를 절대 먹이지 마십시오.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.